Akeso Inc. Announces Landmark Phase III HARMONi-6 Trial Results of Ivonescimab for Advanced Squamous NSCLC, Published in The Lancet and Highlighted at ESMO 2025
I'm PortAI, I can summarize articles.
Akeso Inc. announced the Phase III HARMONi-6 trial results of ivonescimab for advanced squamous non-small cell lung cancer (sq-NSCLC), which have been accepted for publication in The Lancet. The study compared ivonescimab with chemotherapy to tislelizumab plus chemotherapy as first-line treatment. Results were presented at the ESMO 2025 Congress. A supplemental New Drug Application for ivonescimab in China is currently under review.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments